ImmunityBio Future Growth

Future criteria checks 2/6

ImmunityBio is forecast to grow earnings and revenue by 45.4% and 60.5% per annum respectively while EPS is expected to grow by 44.6% per annum.

Key information

45.4%

Earnings growth rate

44.6%

EPS growth rate

Biotechs earnings growth	35.4%
Revenue growth rate	60.5%
Future return on equity	n/a
Analyst coverage	Low
Last updated	18 Aug 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:26CA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	290	-269	-135	N/A	2
12/31/2025	122	-442	-284	N/A	2
12/31/2024	15	-507	-347	N/A	2
6/30/2024	1	-598	-426	-410	N/A
3/31/2024	0	-601	-413	-389	N/A
12/31/2023	1	-583	-397	-367	N/A
9/30/2023	1	-458	-384	-342	N/A
6/30/2023	1	-473	-387	-335	N/A
3/31/2023	1	-430	-406	-347	N/A
12/31/2022	0	-417	-437	-338	N/A
9/30/2022	1	-400	-409	-318	N/A
6/30/2022	1	-376	-393	-311	N/A
3/31/2022	1	-370	-364	-289	N/A
12/31/2021	1	-347	-308	-274	N/A
9/30/2021	0	-323	-283	-260	N/A
6/30/2021	0	-301	-241	-225	N/A
3/31/2021	1	-264	-210	-201	N/A
12/31/2020	1	-222	-173	-172	N/A
9/30/2020	2	-176	-136	-132	N/A
12/31/2019	2	-158	-156	-152	N/A
12/31/2018	3	-84	-76	-67	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 26CA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 26CA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 26CA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 26CA's revenue (60.5% per year) is forecast to grow faster than the German market (5.4% per year).

High Growth Revenue: 26CA's revenue (60.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 26CA's Return on Equity is forecast to be high in 3 years time

ImmunityBio Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

No longer forecast to breakeven

Forecast to breakeven in 2026

Forecast to breakeven in 2025

Recent updates

New major risk - Financial position

Second quarter 2024 earnings released: US$0.20 loss per share (vs US$0.32 loss in 2Q 2023)

ImmunityBio, Inc.'s ANKTIVA® Now Covered by More Than a Dozen Insurance Plans Representing over 100 Million Lives Within Months of FDA Approval

ImmunityBio, Inc Announces Study of ANKTIVA® in Combination with the AdHER2DC Cancer Vaccine as a Potential Therapy to Control Endometrial Cancer

ImmunityBio, Inc. Announces the Initial Treatment of Multiple Patients in the United States to Receive Therapy with ANKTIVA

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.27 loss in 1Q 2023)

ImmunityBio, Inc. Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®

ImmunityBio, Inc., Annual General Meeting, Jun 11, 2024

ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Insufficient new directors

No longer forecast to breakeven

New minor risk - Profitability

Full year 2023 earnings released: US$1.15 loss per share (vs US$1.04 loss in FY 2022)

ImmunityBio Announces Data from A Phase 1 Pilot Study

ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

Forecast to breakeven in 2026

Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes (PROs) of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG

New major risk - Financial position

Third quarter 2023 earnings released: US$0.19 loss per share (vs US$0.28 loss in 3Q 2022)

ImmunityBio, Inc. Announces First Data for Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-Tumor Activity

ImmunityBio, Inc. Announces U.S. Food and Drug Administration Accepts its BLA Resubmission as Complete and Sets New PDUFA Date

ImmunityBio, Inc. Announces Biological License Application Resubmission for N-803 in BCG Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ

New major risk - Shareholder dilution

ImmunityBio, Inc. announced that it has received $200 million in funding from Nant Capital, LLC

ImmunityBio, Inc. announced that it has received $200 million in funding from Nant Capital, LLC

Second quarter 2023 earnings released: US$0.32 loss per share (vs US$0.24 loss in 2Q 2022)

Jakubowitz Law Reminds Immunitybio Shareholders of A Lead Plaintiff Deadline of August 29, 2023

ImmunityBio, Inc. Appoints Enrique Diloné as Chief Technology Officer, Effective August 14, 2023

ImmunityBio, Inc. Announces Findings from a Phase 1 Study Showing Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells

Pomerantz Law Firm Announces the Filing of a Class Action Against ImmunityBio, Inc. and Certain Officers – IBRX

Independent Director recently bought €66k worth of stock

ImmunityBio, Inc., Annual General Meeting, Jun 13, 2023

ImmunityBio, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration Regarding Its Biologics License Application

First quarter 2023 earnings released: US$0.27 loss per share (vs US$0.26 loss in 1Q 2022)

Full year 2022 earnings released: US$1.04 loss per share (vs US$0.89 loss in FY 2021)

ImmunityBio, Inc. announced that it expects to receive $50 million in funding

High number of new directors

Third quarter 2022 earnings released: US$0.28 loss per share (vs US$0.22 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.23 loss in 2Q 2021)

ImmunityBio, Inc. Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma in Situ

ImmunityBio, Inc. Announces Quilt Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer

ImmunityBio, Inc. Submits Biologics License Application for N-803 Plus Bcg for Patients with Bcg-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

First quarter 2022 earnings released: US$0.26 loss per share (vs US$0.21 loss in 1Q 2021)

ImmunityBio, Inc., Annual General Meeting, Jun 14, 2022

High number of new directors

Immunitybio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer

ImmunityBio, Inc. Announces Study Results That Further Demonstrate the Potential for Use of Memory-Like Cytokine-Enriched Natural Killer (m-ceNK) Cells for the Treatment of Cancer

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

ImmunityBio, Inc. Announces Study Results That Further Demonstrate the Potential for Use of Memory-Like Cytokine-Enriched Natural Killer (m-ceNK) Cells for the Treatment of Cancer

ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX).

ImmunityBio, Inc. Announces Positive Data from its Late-Stage Bladder Cancer Trial

ImmunityBio, Inc. Announces Promising Clinical Study Results for Kick and Kill HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy

ImmunityBio, Inc. Announces Interim Results in its Metastatic Pancreatic Cancer Trial

ImmunityBio, Inc. Announces Updates on Its Clinical Year-End Review of Strategic Milestones

Third quarter 2021 earnings released: US$0.22 loss per share (vs US$0.17 loss in 3Q 2020)

ImmunityBio, Inc. Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with A Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-Free in Phase 2/3 Trial

ImmunityBio, Inc. Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19

ImmunityBio, Inc.(NasdaqGS:IBRX) dropped from Russell 3000E Growth Index

Immunitybio, Inc. Receives FDA Authorization to Conduct A Phase 1B/2 Open-Label Study

ImmunityBio, Inc. Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients

Immunitybio, Inc. Expands Trials of T-Cell-Based Covid-19 Vaccine Candidate as A ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa

Board Member recently sold €1.6m worth of stock

FDA Authorizes ImmunityBio to Conduct Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell Platform in Solid Tumors

Forecast to breakeven in 2025

ImmunityBio, Inc. Announces 78% Complete Response Following Chemotherapy-Free Combination of Il-15 Superagonist Anktiva with Rituxan in Relapsed Non-Hodgkin Lymphoma Patients

ImmunityBio, Inc. Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva With Antiretroviral Therapy to Inhibit HIV Reservoirs

ImmunityBio Announces Positive Interim Phase I Safety Data of hAd5 T-Cell COVID-19 Vaccine Candidate in Oral and Sublingual Formulations

ImmunityBio, Inc. Announces Novel ACE2 Decoy COVID-19 Therapeutic that Shows High Binding to SARS-CoV-2 Variants and Neutralizes Live Viruses

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts